EGFR and non-small cell lung carcinoma: Accumulating evidence indicates the potential efficacy of neoadjuvant EGFR-TKIs in patients with resectable NSCLC, which has led to the design of RCTs, notably the phase II EMERGING-CTONG1103 and phase III NeoADAURA trials.